LENZ Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 19, 2025
LENZ$4.29+22.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
| Page No. | ||
|---|---|---|
| PART I | ||
| Item 1. | Business | 3 |
| Item 1A. | Risk Factors | 33 |
| Item 1B. | Unresolved Staff Comments | 86 |
| Item 1C. | Cybersecurity | 86 |
| Item 2. | Properties | 87 |
| Item 3. | Legal Proceedings | 87 |
| Item 4. | Mine Safety Disclosures | 87 |
| PART II | ||
| Item 5. | Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 88 |
| Item 6. | [Reserved] | 88 |
| Item 7. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 89 |
| Item 7A. | Quantitative and Qualitative Disclosures About Market Risk | 97 |
| Item 8. | Financial Statements and Supplementary Data | 98 |
| Item 9. | Changes in and Disagreements with Accountants On Accounting and Financial Disclosure | 125 |
| Item 9A. | Controls and Procedures | 125 |
| Item 9B. | Other Information | 126 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.